A pharmaceutical company that specializes in the production of medication kits used for the treatment of diabetes, ...

Starting treatment in the first month after diagnosis increases the likelihood of blood pressure control with lasting ...

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2025.

Improved hypertension control can save millions of lives, but mass hypertension screening, a commonly used approach, is a barrier to progress. Although politically appealing, mass screening diverts ...

Researchers at UCL have tested a new scoring system to measure the risk of stroke in patients with narrowed arteries due to ...

Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025 District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendment Fully enrolled Cohort A of ...

Hypertension is a major global health challenge, affecting millions and serving as a key risk factor for cardiovascular and renal diseases. While endocrine ...

Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the ...

Every part of my life seemed to improve after nasal surgery, from my allergies to my mental health. Nose breathing is a ...

ASX medtechs are taking brain diagnostics beyond the hospital or clinical settings to the front lines of care for better outcomes.

Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

Cosentyx is the first interleukin-17A (IL-17A) inhibitor approved in Europe, providing a new first-line biologic treatment option for patients and has been shown as superior to Stelara and Enbrel ...